--- a
+++ b/clusters/3009knumclusters/clust_177.txt
@@ -0,0 +1,759 @@
+Allergy or hypersensitivity to components of the cobimetinib formulations
+The subject has a history of allergy or intolerance to flucytosine
+No known allergy to aspirin
+Patients must not have any known allergy or reaction to any component of the durvalumab (MEDI4736) and/or tremelimumab formulation
+Patients must not have prior history of allergy or known hypersensitivity to nivolumab or ipilimumab
+No known allergy to 5-fluorouracil, oxaliplatin, or leucovorin
+Known allergy to boron or excipients in the formulation
+Patients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)
+Patients with a known or documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
+Known allergy to any of the study agents
+Allergy or hypersensitivity to cemiplimab or to any of its excipients;
+Known allergy, hypersensitivity or contraindication to components of the FPA144 formulation including polysorbate or to platinum-containing medications, 5-FU, or leucovorin
+Known allergy or hypersensitivity to any of the study drugs or their excipients.
+History of allergy or hypersensitivity to any study drugs or their excipients
+Allergy or hypersensitivity to components of the KO-947 formulation, e.g. dextrose, hydroxypropyl beta cyclodextrin, acetic acid, sodium acetate and water for injection.
+Known allergy to both xanthine oxidase inhibitors and rasburicase
+A known history of allergy to docetaxel, Cremophor or polysorbate 80 (Tween 80)
+History of allergy to study drug components
+Known allergy to eggs, gentamicin, or platinum containing compounds
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Known allergy to enadenotucirev, nivolumab or their excipients
+Known allergy, hypersensitivity, or contraindication to paclitaxel, docetaxel, or irinotecan or any components used in their preparation
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Allergy to iodine or gadolinium contrast that cannot be safely controlled with premedication
+Patients who have a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent are not eligible
+Known history of positive serum human anti-drug antibody (ADA), or known allergy to any component of ADCT-301
+Prior allergy or adverse reaction to methotrexate
+Previously identified allergy or hypersensitivity to components of the cabozantinib formulations
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+No known allergy or adverse reaction (e.g., wound dehiscence) to poly-lactide-co-glycolide (PLG)
+History of allergy to mannitol or prior hypersensitivity to thalidomide, lenalidomide or pomalidomide
+Previously identified allergy or hypersensitivity to components of the study treatment formulations
+Documented allergy to DMSO, mouse or bovine proteins, or iron.
+History of allergy to study treatments or any of its components of the study arm that participant is enrolling
+Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
+Known allergy or reaction to any component of either study drug formulation
+Known allergy or hypersensitivity to the components of the atezolizumab formulation.
+Known allergy or hypersensitivity to the components of the doxorubicin, cyclophosphamide, carboplatin, or paclitaxel formulations.
+Known allergy or hypersensitivity to liposomal or pegylated G-CSF formulations.
+Patients with a history of allergy to the study drug components are excluded
+Any history of allergy to the study drug components
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known allergy or hypersensitivity to the components of the formulations of atezolizumab, nab-paclitaxel, cyclophosphamide, or doxorubicin, filgrastim or pegfilgrastim
+A history of a severe contrast allergy (i.e. anaphylaxis) not controlled with premedication
+Known allergy/intolerance to soy, phosphatidylcholine or any other constituents of grape seed extract
+Patients with a latex allergy
+Known in tolerance and allergy to cytarabine.
+The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments
+History of allergy to study drug components
+Previous known allergy or intolerance to pembrolizumab or any of its excipients
+Previous exposure or known allergy to Imprime PGG or any of its excipients
+Known allergy or hypersensitivity to any component of the atezolizumab formulation
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
+Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for tumor lysis syndrome
+Known allergy to grapes or grape seed
+History of allergy to study drug components
+Has had previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2 inhibitor.
+History of allergy or intolerance to study drug components or polysorbate-80-containing infusions
+Have a history of allergy to iodinated contrast media
+Allergy to benzamide or inactive components of entinostat.
+Known allergy or hypersensitivity to phosphatidylinositol 3 kinase (PI3K) inhibitors or any component of the formulations used in this study.
+Known allergy to any of the study medications, their analogues or excipients in the various formulations
+Previous history of hypersensitivity to eggs or allergy or untoward reaction to prior vaccinia (smallpox) vaccination
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+DONOR: Known allergy to filgrastim (G-CSF)
+Bovine product allergy
+Known or suspected allergy or hypersensitivity to the study drug
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Allergy to measles vaccine or history of severe reaction to prior measles vaccination
+Allergy to iodine; (NOTE: this does not include reactions to intravenous contrast materials)
+Patients with a suspected allergy or sensitivity to any component of MT-3724 drug preparation based upon known allergies to compounds of a similar class who have had an anaphylactic or other severe infusion reaction to human immunoglobulin or monoclonal antibody administration are n ot eligible.
+Allergy to shellfish
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
+Milk allergy
+Allergy or sensitivity to irinotecan or cranberry-grape juice, or any of the irinotecan tablet excipients. .
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known history of contrast allergy that cannot be medically managed
+EXCLUSION - TREATMENT: Known allergy to VZV vaccine
+Known allergy to any of the study medications, their analogues or excipients in the various formulations
+Known allergy to HCQ
+History of grade >= 3 allergy to human monoclonal antibodies
+Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
+Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded
+Patients with known allergy or hypersensitivity to AG120 or venetoclax.
+Known allergy to both xanthine oxidase inhibitors and rasburicase
+Doxycycline allergy
+Allergy or intolerance to roflumilast
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Participants must not have a history of allergy to nivolumab, urelumab or cabiralizumab
+Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
+The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
+History of allergy or hypersensitivity to study drug components
+Known allergy or reaction to any component of either study drug formulation
+History of gastritis or malabsorption syndrome or aspirin intolerance or allergy
+History of allergy to study drug components.
+A previously identified allergy or hypersensitivity to components of the study treatment formulation.
+Any history of allergy to the study drug components
+Known allergy to the study drugs or any of its components
+Bupivacaine or liposomal bupivacaine sensitive or known allergy.
+Known allergy or hypersensitivity to any of the study drugs or any of their excipients
+Any history of allergy to the study drug components
+Subjects with an allergy to contrast agents may be enrolled at the treating physician’s discretion with appropriate pre-treatment and symptom management
+Known allergy or reaction to any component of either study drug formulation
+Known allergy to anthracyclines.
+Previously identified allergy or hypersensitivity to any component of the study treatment formulations
+Allergy to any component of MSC suspension (such as human albumin) and/or allergy to any drugs used in HCT conditioning regimen
+History of allergy to merestinib or chemically related compounds
+An allergy or intolerance to egg, gluten or milk protein
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+An allergy to a component of Levulan
+History of allergy or intolerance (unacceptable adverse event) to study drugs components.
+Subject has known history of allergy, hypersensitivity, or any serious reaction to any of the azole class antifungals.
+Has an allergy or hypersensitivity to chili peppers, capsaicin, or radiographic contrast agents.
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Patient has a history of allergy to red color food dye or any other component of Qapzola, placebo, or their diluents
+Known allergy to both xanthine oxidase inhibitors and rasburicase; or, known hypersensitivity to any of the study drugs
+Previously identified allergy or hypersensitivity to components of the study treatment formulations
+Allergy to benzamide or inactive components of entinostat
+Known allergy or intolerance to any component of belimumab, including human or murine proteins or monoclonal antibodies
+Known allergy or hypersensitivity to IP
+Allergy or hypersensitivity to components of the cobimetinib formulation
+Known allergy to any of the study medications, their analogues or excipients in the various formulations
+have a known or suspected allergy to the study drug or any study drug component;
+Allergy to carfilzomib or cabozantinib or any excipients
+Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
+Has known allergy or reaction to any component of either study drug or formulation components
+History of allergy to mouse proteins
+History of allergy to study drug components
+History of sensitivity or allergy to monoclonal antibodies (mAbs) or immunoglobulin G (IgG)
+Known allergy to murine proteins or have had a documented anaphylactic reaction to any drug, or a known hypersensitivity to diphenhydramine or other antihistamines of similar chemical structure.
+Known hypersensitivity or allergy to any component of the avelumab formulation
+Has a previously identified allergy or hypersensitivity to components of the study treatment formulations
+Known allergy or hypersensitivity to intraperitoneal (IP) or any excipient
+Allergy to murine-based monoclonal antibodies
+Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
+History of allergy to study drug components
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Known allergy to grapes or grape seed
+Allergy to pembrolizumab or related compounds
+Known allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug formulations.
+Patients with unconfirmed allergies to piperacillin-tazobactam, cefepime, aztreonam or vancomycin can be evaluated by an allergy/immunology specialist, after which they may become eligible by a consensus of the treating physician, trial investigator and the allergy/immunology specialist
+A known allergy or history of hypersensitivity to silicon, phosphorous or any of the OncoSil™ components
+Patients with a known allergy to Zometa or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
+History of grade 3 or higher allergy to humanized monoclonal antibodies
+Known allergy or intolerance to lidocaine
+Patients with a known hypersensitivity/allergy to any of the standard of care agents used in this study or related compounds (e.g. platinum compounds) are excluded
+Patients with albumin allergy
+Gadolinium allergy
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Patients with an allergy, or have experienced any drug reaction to ketamine will be excluded
+History of allergy to study drug components
+Allergy to benzamide or inactive components of entinostat
+Known allergy to coenzyme Q10
+Known allergy or adverse reaction to oral, subcutaneous, or intravenous vitamin K
+Known allergy or hypersensitivity to any component of the investigational drug product.
+Known allergy to doxycycline or tetracycline
+History of allergy or adverse drug reaction to study components
+Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)
+Known allergy or hypersensitivity to investigational product (IP) or any excipient
+Known allergy to ODM-201 or any of the excipients.
+Known allergy to both xanthine oxidase inhibitors and rasburicase
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+History of allergy to study drug components
+History of allergy to components of nivolumab or DS-8273A, or known allergy to other antibody therapies
+Known or suspected allergy to lenvatinib or any agent given in the course of this trial
+Known allergy to any of the study medications, their analogs, or excipients in the various formulations of any agent
+Any known allergy or allergic reactions to Captisol
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; specifically, prior desquamating rash or erythema nodosum during prior thalidomide or other similar agents
+History of severe allergy (e.g., anaphylaxis) to any component of Prevnar or any diphtheria?toxoid containing vaccine
+Known allergy or hypersensitivity to study drug formulations
+History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
+History of allergy or hypersensitivity to albumin-bound paclitaxel, or gemcitabine
+Patients with known allergy to cremophor or polysorbate 80
+Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
+Known allergy to PIO
+Patients may not have any known allergy to CYP and/or GM-CSF.
+Allergy to measles vaccine or history of severe reaction to prior measles vaccination
+Allergy to iodine; Note: this does not include reactions to intravenous contrast materials
+Known allergy to any of the study medications, their analogues or excipients in the various formulations
+Allergy to X ray contrast agents.
+Severe allergy to contrast agent.
+Allergy or hypersensitivity to agents used within the treatment protocol
+History of allergy to mouse proteins
+Patients who have known allergy to mebendazole
+History of sensitivity or allergy to monoclonal antibodies or immunoglobulin G
+Known history of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and dextran 40)
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; patient cannot be allergic to boron
+Allergy or hypersensitivity to components of the vemurafenib formulation
+History of allergy to study drug components
+CERITINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of ceritinib formulation
+REGORAFENIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of regorafenib formulation
+ENTRECTINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of entrectinib formulation
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Patient has a history of allergy or intolerance to flucytosine.
+Patients with known allergy or hypersensitivity to selinexor, sorafenib or any of its components
+Known allergy or hypersensitivity to tetanus, or any other tetanus or diphtheria toxoid-containing vaccine, or any component of this vaccine (i.e., aluminum phosphate, formaldehyde)
+Known allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
+Known or suspected allergy or hypersensitivity to regorafenib, or excipients of the formulations given during the course of this trial
+Previously identified allergy or hypersensitivity to components of the study treatment formulations
+Have known severe intolerance to or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous immunoglobulin preparations; any history of anaphylaxis; prior history of human anti-human antibody response; known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Patients with known carboplatin or cisplatin allergy
+History of allergy to study treatments or any of its components of the study arm that participant is enrolling
+History of allergy to study drug components
+Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.
+Known allergy to sulfa or specific allergy to sulfonylurea drugs
+Allergy to gadolinium
+Known allergy, hypersensitivity or prior infusion reaction to one or more of the therapies incorporated into this treatment protocol
+Patients with a known allergy to cisplatin chemotherapy; patients with carboplatin allergy may be included if they tolerate a test dose of intravenous (IV) cisplatin given in monitored floor conditions
+Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Patients with known allergy or hypersensitivity to nivolumab, ipilimumab, 5-azacytidine, or any of their components
+Allergy to filgrastim, pegfilgrastim, or loratadine
+History of allergy to mannitol
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Patients must not have a known history of yeast allergy; if patient has a questionable history of allergy to yeast, a yeast skin test can be performed; patients would be eligible if skin test is negative (note, patients may not be on tricyclic antidepressants at the time of yeast skin test)
+Patient does not have known allergy to polyethylene glycol hydrogel (spacer material)
+Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
+Known allergy to ixazomib, its analogues, or excipients in the various formulations of ixazomib
+Gold allergy
+History of allergy or hypersensitivity to nivolumab components
+Patients with a known allergy to gadolinium-DTPA
+A previously identified allergy or hypersensitivity to components of the study treatment formulation
+Known history of allergy to Captisol®
+Known or suspected allergy or hypersensitivity to sorafenib
+History of allergy to study drug components
+Known allergy or reaction to any component of the MEDI4736 formulation or its excipients
+Patients with known allergy, intolerance, or resistance (i.e., remission duration less than 6 months or lack of response) to ifosfamide, carboplatin, or etoposide
+Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty
+Patients with a known allergy to dimethyl sulfoxide (DMSO)
+Allergy or hypersensitivity to tetanus vaccine or any component of the tetanus vaccine
+Known allergy to fluoropyrimidines or known dihydropyrimidine dehydrogenase (DPD) deficiency.
+Patients with a known history of a severe allergy or sensitivity to wheat gluten
+MAIN STUDY COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibi
+The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
+Subjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatum
+History of allergy to mouse proteins
+Allergy to measles vaccine or history of severe reaction to prior measles vaccination
+Allergy to iodine; this does not include reactions to intravenous contrast materials
+The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
+Patients with NSAIDs allergies, known lactose allergy, a history of recent gastrointestinal (GI) bleed (less than 2 weeks), and those who are on therapeutic dose anticoagulants will be excluded from this protocol
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize CFZ), or similar chemical or biologic composition to bendamustine or other agents used in the study
+Patients with a known allergy to any component of the study treatment formulations
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Must not have any known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
+History of allergy to penicillin or related antibiotic
+Patients with known allergy or hypersensitivity to quizartinib, mannitol, AZA, cytarabine or any of their components.
+Previously identified allergy or hypersensitivity or intolerance to components of the study treatment formulation (cyclophosphamide, capecitabine, lapatinib [lapatinib ditosylate], trastuzumab)
+Patients with an allergy or known hypersensitivity to fish
+Known allergy to any of the agents or their ingredients used in this study
+Known allergy to sargramostim (GM-CSF)
+Patients who are known to have allergy to mouse proteins
+Allergy to valacyclovir or unable to take oral tablets
+History of allergy to mouse proteins
+History of allergy to GM-CSF
+Allergy to oseltamivir or excipients
+Known allergy to domperidone
+Known severe or life-threatening allergy or intolerance to fludarabine, alemtuzumab, cyclosporine, or mycophenolate mofetil.
+COHORTS 1 AND 2: HEALTHY VOLUNTEERS: Known allergy or sensitivity to sodium hypochlorite (NaOCl)
+Known or suspected allergy to sorafenib, everolimus, or any agent given in the course of this trial
+Patients with latex allergy.
+Known allergy to any of the study medications, their analogues or excipients in the various formulations
+Known allergy to any of the treatment components
+History of allergy to mouse proteins
+Patients who have an allergy to gold.
+Corn allergy
+History of allergy to KLH, QS-21, OPT-821, or glucan
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+History of allergy or hypersensitivity to any systemically administered antibody agent or its excipients
+Known allergy/hypersensitivity to drug or components
+Patients may not have any known allergy to CYP and/or GM-CSF.
+History of photosensitizing disease (porphyria, lupus etc.) or of allergy to methylene blue dye.
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Patients who have a known history of allergy to Captisol (a cyclodextrin derivative used to stabilize carfilzomib) are NOT eligible for participation
+Patients are excluded if there is any history of gadolinium allergy.
+Patient having known allergy to NSAID or Aspirin
+Known allergy to doxorubicin or anthracyclines.
+History of allergy or hypersensitivity to gemcitabine (or other drug excipients in TAR-200) or drugs chemically-related to gemcitabine.
+History of allergy or hypersensitivity to the device constituent or Inserter materials.
+History of allergy or hypersensitivity to nivolumab drug components.
+Known allergy or hypersensitivity to the components of the atezolizumab formulation or to any of the study drugs or excipients, (e.g., Cremophor EL)
+Subjects with hypersensitivity or allergy to tetracycline antibiotics or edetate disodium;
+History of allergy or hypersensitivity to any of the study drugs.
+Known allergy or hypersensitivity to any of the study drugs
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
+Patient has a prior allergy or intolerance of ketoconazole
+Patient has an allergy or intolerance to sulfites
+Patients with known allergy to MB
+Previously identified allergy or hypersensitivity to components of the study treatment formulations
+Known allergy(ies) to any component of CMB305 or LV305.
+Known allergy or hypersensitivity to study treatment or any of the study drugs excipients.
+Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty.
+History of allergy to or intolerance of ibrutinib or lenalidomide
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Allergy to measles vaccine or history of severe reaction to prior measles vaccination
+Known allergy to hyaluronidase
+Allergy to brentuximab vedotin and/or nivolumab
+History of allergy or hypersensitivity to any of the study drugs or study drug components
+Allergy to measles vaccine or history of severe reaction to prior measles vaccination
+Allergy to iodine\r\n* Note: This does not include reactions to intravenous contrast materials
+Allergy to measles vaccine or history of severe reaction to prior measles vaccination
+Dose Escalation cohort only: Allergy to iodine; NOTE: this does not include reactions to intravenous contrast materials
+DOSE ESCALATION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugs
+DOSE EXPANSION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugs
+Any history of allergy to the study drug components
+History of allergy to study drug components.
+Patients with prior allergy to daunorubicin and/or cytarabine
+Patients with known allergy to intravenous iodinated contrast agents
+Patients who have an allergy/intolerance to sirolimus
+The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
+DONOR: Known allergy to filgrastim (GCSF)
+Allergy to measles vaccine or history of severe reaction to prior measles vaccination
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+History of allergy or hypersensitivity to any component of the treatment
+History of severe environmental allergies or allergy to egg proteins
+Allergy to or intolerance of prior doxorubicin-based TACE
+Allergy to or intolerance to iodinated contrast media despite standard of care pre-medication
+Known or suspected allergy or hypersensitivity to any of the study drug classes
+Known allergy to bevacizumab or brentuximab vedotin or any of its excipients
+History of allergy to egg proteins
+Known history of allergy to Captisol®
+Soy allergy
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+History of allergy or untoward reaction to prior vaccination with vaccinia virus
+Known allergy or hypersensitivity to azacitidine, mannitol, or midostaurin
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Patients must not have any known allergy or reaction to any component of the nivolumab and ipilimumab formulations
+Local or severe allergy to any components of the drug regimen.
+History of allergy or hypersensitivity to nab-paclitaxel or carboplatin. 9. Currently enrolled in any other clinical protocol or investigational trial that involved administration of experimental therapy and/or therapeutic devices.
+Patient must not have a known allergy to any of the treatment components
+Known allergy or hypersensitivity to components of the FPA144 formulation including polysorbate
+Known history of positive serum human ADA, or known allergy to any component of ADCT-301.
+Known allergy(ies) to any component of CMB305 or CPA
+Subject has a history of allergy or hypersensitivity to any study drugs or their excipients.
+For the Combination Dose Finding and Combination Expansion cohorts only: previously identified allergy or hypersensitivity to components of the study treatment formulation or panitumumab
+Patients with known floxuridine, leucovorin (leucovorin calcium), or mitomycin (mitomycin C) allergy
+Known allergy to boron, MLN9708, any of the study treatments, their analogues, or excipients.
+History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
+Allergy or contraindications to administration of the GI anti-spasmodic drug:
+Patients must not have any known allergy or reaction to any component of the MEDI4736 formulation
+Subject has a history of allergy or hypersensitivity to study drug components;
+Known allergy to both penicillin and sulfa antibiotics
+Known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for TLS
+Prior demonstrated hypersensitivity, intolerance or allergy to abiraterone acetate, prednisone or their excipients
+No known allergy to platinum compounds
+History of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies, nivolumab or related compounds
+History of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodies
+Known or suspected allergy to any agent given in the course of this trial
+History of severe allergy or intolerance to contrast agents, narcotics sedatives or atropine that cannot be managed medically
+Known allergy to latex or gadolinium (Gd).
+Known allergy or hypersensitivity to any component of the atezolizumab formulation
+Known allergy or hypersensitivity to any component of the bevacizumab formulation
+have a known allergy or hypersensitivity reaction to any of the treatment components
+Have a known allergy or hypersensitivity reaction to any of the treatment components.
+Allergy to ciprofloxacin (or other quinolones), acetylsalicylic acid, or indomethacin.
+Known allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.
+Patients with known allergy or hypersensitivity to lirilumab, 5-azacytidine, or any of their components; patients who have previously been treated with lirilumab in combination with 5-azacytidine will be excluded
+Have a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.
+Known allergy to iron dextran or presence of human anti-mouse antibodies
+Have known allergy or hypersensitivity to any components of study treatment.
+History of allergy to murine proteins
+History of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)
+A history of allergy to human monoclonal antibodies.
+Patients with known allergy to sorafenib or azacitidine, mannitol or any of their components
+Known or suspected allergy to sorafenib or any agent given in the course of this trial
+Known allergy(ies) to any component of the study agent GLA-SE including egg lecithin
+History of allergy to murine proteins
+History of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)
+Have a known allergy to tomatoes or have never consumed tomatoes
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+History of allergy to components of ipilimumab or panobinostat, or known allergy to other antibody therapies
+Known allergy to thalidomide.
+Patients must not have a known allergy to mannitol
+The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
+Subject has a known allergy to ART-123 or any components of the drug product.
+Allergy to ganciclovir or acyclovir
+History of allergy to mouse proteins
+Subjects with known allergy or hypersensitivity to any component of the investigational product will be excluded
+Known allergy to both xanthine oxidase inhibitors and rasburicase
+Allergies and Adverse Drug Reaction: History of allergy to study drug components
+History of allergy to study drug components
+Has known or suspected allergy or sensitivity to any test materials, reagents, or WCE contrast materials
+Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enroll
+Known allergy or hypersensitivity to IP formulations or to other human monoclonal antibodies
+Patient has a history of allergy to red color food dye.
+A known allergy to any component of LY2157299.
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+History of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Known allergy to hyaluronidase
+The participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or pembrolizumab, or any other contraindication to one of the administered treatments.
+Allergy to meclofenamate or other nonsteroidal antiinflammatory drug (NSAID)
+History of allergy or intolerance (unacceptable adverse event) to study drugs components
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Previously identified allergy or hypersensitivity to components of the study treatment formulations
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Known allergy or hypersensitivity to paclitaxel or any components used in the paclitaxel preparation or other contraindication for taxane therapy
+Known allergy to any of the vaccine or adjuvant components, including eggs
+Known allergy or hypersensitivity to Investigational Product.
+Patients with documented allergy to cephalosporins
+Patients may not have a known allergy or hypersensitivity to any of the components of the investigational therapy, including polyethylene glycol (PEG) or topoisomerase inhibitors
+Has allergy to enzalutamide
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Patient has a known allergy to both penicillin and sulfa
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
+All patients who have received prior vaccination with vaccinia virus (for smallpox immunization) must not have a history of allergy to the vaccine
+Patients with known allergy to eggs
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Known or suspected allergy to sorafenib or any agent given in the course of this trial
+Known history of allergy to Captisol
+No known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Known allergy to both xanthine oxidase inhibitors and rasburicase
+Allergy or hypersensitivity to components of the cobimetinib formulations
+Patients who have a history of allergy to iodides or iodinated contrast agents
+Patients with a known allergy to murine proteins or have had a documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, oregovomab, or to antiemetics appropriate for administration in conjunction with protocol-directed therapy
+Known allergy to any of the drugs used in the study. (Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.)
+Known allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine
+An allergy to iodine
+Known allergy or adverse drug reaction to nivolumab, or a history of allergy to study drug components
+Known or suspected allergy to gemcitabine or MLN8237, or any agent given in the course of this trial
+Known or suspected allergy to irinotecan or MLN8237, or any agent given in the course of this trial
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+History of allergy or hypersensitivity to any component of the study drugs
+Known allergy to any of the study medications
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.
+The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
+Known or suspected allergy to gemcitabine or cisplatin
+History of allergy to mannitol
+A known allergy to any component of the HyperAcute®-Lung immunotherapy or cell lines from which it is derived.
+Known allergy to any of the treatment components
+Known allergy to bortezomib, boron, or mannitol
+Patients who have known allergy to mebendazole or benzimidazole
+Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations
+The patient has known allergy to any of the treatment components
+Allergy or hypersensitivity to agents used within the treatment protocol
+Known allergy to any of the compounds under investigation
+Have a known allergy to resiquimod or any of the excipients in the study drug
+Known or suspected allergy or hypersensitivity to yeast or any other component of CRS-207 (e.g., glycerol), Platinol or platinum-containing compounds, or pemetrexed
+The subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
+Medically diagnosed lactose intolerance, lactose allergy or salicylate allergy
+The participant has a previously identified allergy or hypersensitivity to components of the study treatment formulation
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
+If patients meet any of the following they will be excluded:\r\n* Active infection requiring intravenous treatment or having an unexplained febrile illness (temperature maximum [Tmax] > 99.5 Fahrenheit [F]/37.5 Celsius [C])\r\n* Known immunosuppressive disease or known human immunodeficiency virus infection\r\n* Unstable or severe intercurrent medical conditions such as severe heart (New York Heart Association class 3 or 4) or known lung (forced expiratory volume in 1 second [FEV1] < 50%) disease, uncontrolled diabetes mellitus\r\n* Albumin allergy; patients with a known allergy will be excluded\r\n* Gadolinium allergy
+Known allergy to any of the study medications, their analogues or excipients in the various formulations
+History of known allergy or contraindications to the use of pazopanib, paclitaxel, or carboplatin
+Known allergy to gadolinium
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Known or suspected allergy to pazopanib
+18F FLT CANDIDATE TRANSPLANT RECIPIENT: History of prior fluorothymidine allergy or intolerance
+Subjects with known allergy or hypersensitivity to doxorubicin, cyclophosphamide, or eribulin mesylate.
+History of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy
+Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
+Patient has a known allergy to any component of the study treatment formulations
+Allergy to valproic acid
+Known or suspected allergy to ARQ 197
+Allergy to benzamide or inactive components of entinostat
+History of allergy to study drug components
+Previously identified allergy or hypersensitivity to components of the study treatment formulations.
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Patients with a history of allergy to entinostat or other medications that have a benzamide structure (i.e. tiapride, remoxipride, and clebopride)
+History of allergy or reaction to any component of the MEDI-551 formulation
+Known allergy to allopurinol for subjects assessed with PR following their second-line induction therapy.
+Patients with a known allergy to any component of vorinostat, or a known allergy to temozolomide and/or isotretinoin.
+Known or suspected allergy to sorafenib (BAY 43-9006) or any agent given in association with this trial
+Patients with known allergy to etoposide or a history of grade 3 hemorrhagic cystitis with cyclophosphamide are not eligible
+DONOR: Known allergy to filgrastim (G-CSF)
+DONOR: Known allergy to G-CSF
+Patients will be excluded if they have a known allergy to any of the drugs used in the study
+History of severe allergy to any of the components of NEOD001 such as histidine/L-Histidine, Trehalose, or Polysorbate 20
+Has known allergy or history of adverse reaction to ICG, iodine or iodine dyes.
+Allergy to measles vaccine or history of severe reaction to prior measles vaccination.
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.
+Known allergy to bone cement,
+Patients will be excluded if they have a known allergy to any of the drugs used in the study.
+Any known allergy to the compounds under investigation
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Patients with known allergy or hypersensitivity to IMGN901
+Known allergy to wheat, rice (contained in the placebo), orange or the sweetener, Stevis
+A known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.
+Known allergy to hyaluronidase or any constituents of docetaxel formulation.
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Subject has a history of allergy or hypersensitivity to nab-paclitaxel or gemcitabine or any of their excipients.
+Known or suspected grade 3 allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Bovine product allergy
+Known allergy to any of the study drugs
+Known allergy to BCG or MMC
+Known or suspected grade 3 allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known allergy or hypersensitivity to any of the formulation components
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Prior history of penicillin or streptomycin allergy
+Known intolerance or allergy to MR contrast agent (gadolinium chelates) including advanced kidney disease
+Patients with a soy allergy will be excluded
+Known allergy or hypersensitivity to any component of the study treatment(s)
+History of severe allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
+Known or suspected allergy to the investigational agents or any agent given in association with this trial (hypersensitivity reaction, hives, rash, difficulty breathing swelling of your face, lips, tongue, or throat)
+Patient has a history of allergy or hypersensitivity to the study drugs
+History of hypersensitivity or allergy to study drugs, aspirin, sulfonamides, or NSAIDs
+The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
+The subject has a known allergy to tetracycline
+Patient has a history of allergy or hypersensitivity to the study drugs
+Known allergy to macrolide antibiotics
+Known allergy to eggs, gentamicin or platinum-containing compounds
+Known allergy to any of the study agents
+History of allergy to nivolumab components
+Allergy to either of the study medications or 5-fluorouracil
+Nut allergy
+Subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulation
+Allergy or hypersensitivity to components of either study drug formulation
+Known allergy to any study drug or ingredient contained in the drug formulation of any of the study drugs.
+Allergy or hypersensitivity to components of the cobimetinib or GDC-0994 formulation
+Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
+Known allergy or history of adverse reaction to ICG, iodine or iodine dyes.
+Known allergy or history of adverse reaction to Blue dye (Isosulfan blue) or triphenylmethane.
+Known allergy to paclitaxel or any of its components
+History of Grade ? 3 allergy to human monoclonal antibodies.
+Known allergy to any of the components used during vertebroplasty (polymethyl methacrylate [PMMA] bone cement)
+Allergy to implant materials or dental glue.
+Patients with known sensitivity or allergy to any components of AMP-224
+History of severe environmental allergies or allergy to egg proteins
+Known allergy to any of the study drugs or their excipients.
+Patient who has a history of allergy or hypersensitivity to any of the study drugs
+Known hypersensitivity/allergy to fluconazole or itraconazole or their respective excipients.
+Allergy or hypersensitivity to components of the cobimetinib formulations
+Does the subject have a history of allergy or intolerance to flucytosine?
+The patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulations.
+Subjects with a known history of allergy to paclitaxel. Subjects whose allergy was due to the IV solvent (such as Cremophor®) and not paclitaxel will be eligible for this study.
+Known allergy to treatment medication (vemurafenib)
+The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
+Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.
+Known allergy to study medications
+History of significant drug-related allergy (such as anaphylaxis)
+Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)
+Patients with known allergy/hypersensitivity to warfarin or bupropion and/or related compounds
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
+The subject has a previously identified allergy or hypersensitivity to components of the study treatment formulation
+Known allergy or hypersensitivity to any component of the formulation of CA-4948 used in this study
+Known allergy to doxycycline or other tetracycline antibiotics
+Allergy to mannitol
+Known history of allergy to Captisol(a cyclodextrin derivative used to solubilize carfilzomib).
+Known or suspected allergy or hypersensitivity to any component of TH-302, sorafenib, or any of the sorafenib excipients
+History of allergy to Urelumab (BMS-663513) or related compounds
+History of significant drug allergy (such as anaphylaxis or hepatotoxicity) to a prior biologic therapy
+Known or suspected hypersensitivity to any component of GVAX Pancreas vaccine or CRS-207, or known allergy to both penicillin and sulfa
+Known allergy to any of the study medications
+Known or suspected allergy to sorafenib
+The patient has a known allergy/history of hypersensitivity reaction to any of the treatment components.
+Known or suspected allergy to sorafenib or any agent given in the course of this trial
+Allergy / history of hypersensitivity reaction to any of the treatment components
+allergy or intolerance to 5-FC
+Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
+Subject has known sensitivity or allergy to heparin
+Known or suspected allergy to any agent given in the course of this trial
+History of allergy or hypersensitivity to nab-paclitaxel, albumin or a taxane
+Allergy: known hypersensitivity to other recombinant human antibodies
+Known allergy to eggs
+Known severe or life-threatening allergy or intolerance to ATG or cyclosporine/ tacrolimus
+History of allergy to study drug components
+Patients with known allergy or hypersensitivity to ponatinib, or 5-azacytidine, or any of their components
+Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
+Allergy to gadolinium
+Allergy or hypersensitivity to components of the vemurafenib formulation
+Known allergy to any of the agents or their ingredients used in this study
+Allergy to bupropion
+Known allergy to adhesive tape
+Known allergy to EACA
+Allergy to allopurinol
+known allergy to both penicillin and sulfa drugs
+Is known or suspected to have an allergy to opioids, muscle relaxants or other medications used during general anesthesia
+Allergy to egg or egg byproducts
+Women with dialysis, chronic urinary infection, hyperthyroidism, current infection, or a history of allergy or sensitivity to iodine will not be eligible to participate
+Known history of allergy or intolerance to montelukast, zafirleukast, azithromycin, erythromycin, clarithromycin, prednisone, or sirolimus
+Allergy to botulinum toxin, and or egg
+Known sensitivity or allergy to fish or fish oil
+Fish and/or fish oil allergy or intolerance
+Milk allergy excluding lactose intolerance
+Allergy or intolerance to bupivacaine or “amide” anesthetics
+Known allergy to soy or any soy-based food or supplement
+Known allergy to local anesthetics
+Known allergy to perampanel
+Known allergy to or prior intolerance of aspirin and/or simvastatin
+History of an allergy to romiplostim
+Patients with known sensitivity or allergy to porcine materials
+Known allergy to the standard of care or ingredients in KeraStat Cream
+History of allergy to fentanyl
+Allergy treatment with antigen injections
+Allergy or adverse reaction to local anesthesia catheter
+Known true tape allergy
+No known allergy to ingredients of banana bread preparation (eggs, almonds and other nuts since the celery also has almond powder)
+Known allergy to stevia
+History of known allergy to components of the study supplements
+Allergy or intolerance to 5HT3 or NK-1 antagonists and dexamethasone
+Allergy treatment with antigens injections
+Patients with a known allergy or hypersensitivity to CHG are ineligible
+Patients with an allergy to quinolones
+Patients must have no known allergy or hypersensitivity to duloxetine or any of the inactive ingredients in the matching placebo
+Known allergy to a probiotic preparation
+Food allergy to any component of the supplement
+History of allergy to investigational agent: ropivacaine or other amino amide analgesics
+History of allergy to standard agent: propofol
+Allergy to fentanyl
+Allergy to gabapentin
+No known allergy to diphenhydramine, lidocaine, antacid (aluminum hydroxide, magnesium hydroxide, and simethicone), doxepin, tricyclic antidepressants, or any known component of the drug formulation in the testing arms
+Antibiotic allergy to study medication
+Allergy to bone morphogenetic protein
+Known allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enroll
+Known allergy to any of the treatment components.
+Allergy or hypersensitivity to components of the emactuzumab formulation or to components of the atezolizumab formulation
+Arm C: Patients with a methotrexate allergy are excluded
+Previous intolerance/adverse effect/allergy to any component of the placebo or active agent
+Allergy to beef
+History of allergy to fentanyl
+History of allergy to fentanyl
+Participant has a known allergy to melatonin or any ingredients of the study product or placebo
+Patients with a history of skin allergy to iodine or adhesive drapes
+Patients must not have an allergy to latex
+Patients with history of allergy or adverse reactions to sodium bicarbonate or normal saline
+No known allergy to either ACE inhibitors or ?-blockers
+Known allergy to phenylephrine
+Doxycycline allergy
+Allergy to sugar substitute
+Allergy to gabapentin
+Have sensitivity or allergy to fish and/or shellfish
+Have sensitivity or allergy to soy and/or soybeans
+Allergy to either Eucerin or MF
+Known allergy or preexisting skin disease which prohibits use of menthol
+Patients with a history of allergy or adverse reaction to corticosteroids
+Prior history of (H/O) severe allergy or asthma requiring active treatment
+Patients with a history of allergy to human proteins
+Known allergy to a probiotic preparation
+Allergy or prior reaction to the fluorescent contrast agent proflavine
+Allergy or intolerance to gadolinium
+Allergy or prior reaction to the fluorescent contrast agent proflavine
+Participants who have a known allergy to contrast media.
+Participants who have a known allergy to contrast media
+History of allergy to acetic acid
+History of allergy to apixaban or Factor Xa inhibitors
+History of any significant drug allergy (such as anaphylaxis or hepatotoxicity
+Documented allergy to iron dextran or murine proteins
+Allergy to any component of the HPV vaccine including yeast and aluminum
+Known allergy to electrode adhesives or woven knit compression fabrics
+RECIPIENT: Allergy treatment with antigens injections
+Have known hypersensitivity or allergy to eggs, egg or chicken protein, or other components of the study vaccine
+Known allergy to LCM or LEV
+Known history of allergy to any component or other contraindications to any Neurokinin-1 (NK1) or 5-hydroxytryptamine 3 (5-HT3) receptor antagonists.
+Individuals with a known allergy to lidocaine are not eligible
+History of allergy or intolerance to ISA
+Patients with known allergy to boron or boron-containing products, or excipients in the various formulations of any agent
+Women with a known allergy to proflavine, acriflavine, or iodine
+Women with an allergy to rapamycin or its derivatives
+Any known allergy or hypersensitivity to vaginal lubricants or any component of study product
+Documented allergy to apixaban and/or enoxaparin
+Allergy to nicotine patch, nicotine lozenge, or varenicline
+Known sensitivity or allergy to fish
+Patient has allergy to fish or is a vegetarian
+Patients who have an allergy to eggs
+Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)
+Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)
+Known sensitivity or allergy to turmeric spices or curry
+Bovine product allergy.
+Subjects with a known allergy to lidocaine
+Patients with an allergy to Peridex/chlorhexidine solution
+Any serious egg allergy or prior serious adverse reaction to an influenza vaccine
+Has a history of significant allergy to calcitriol as determined by the investigator.
+Allergy to yeast or any of the components of Gardasil
+Has known allergy to Tc99m sestamibi
+Iodide or seafood allergy
+History of allergy to any of the components of OTL38, including folic acid
+History of allergy or hypersensitivity to any component of the treatment
+Women with a known allergy to proflavine or acriflavine
+Subjects with known hypersensitivity and allergy to iron
+Known allergy to adhesive tapes or other skin adhesives used in medical care
+Known prior allergic reaction to ICG or allergy to iodine
+Allergy to sulfa or sulfa-containing medications
+Allergy to sulfa or sulfa-containing medications
+History of allergy to iodide drugs or shellfish (iodine allergy)
+Any known allergy or prior reaction to fluorescein
+Prior history of hypersensitivity to pegylated liposomal doxorubicin or indocyanine green (ICG) allergy; caution should be taken if prior ICG allergy is noted
+Women with iodine contrast allergy
+Women with gadolinium contrast allergy
+Subjects with contraindications to the use of [18F] FAZA including confirmed allergy.
+Subject has an allergy against iodinated contrast agents and cannot be premedicated
+Allergy to gadolinium containing contrast media
+History of iodinated contrast allergy
+Known allergy to FDG or gadolinium based contrast agents
+Any known allergy or prior reaction to fluorescein, iodine, or shellfish
+Patients with a known allergy to Benadryl
+Patients with a known allergy or hypersensitivity to MRI contrast agents including gadolinium
+Known allergy to gadolinium or the sedative, propofol, used during MRI
+Subjects with established allergy to IV GBCA
+Patients with history of allergy to hydrogel dressing or ongoing skin diseases
+History of serious allergy or reaction to any component of RICE or RDHAP formulations that would prevent administration
+Patients with a known allergy to MR contrast agents
+Has known allergy to Tc 99m sestamibi
+Participants who have a known allergy to contrast media
+History of prior fluorothymidine allergy or intolerance
+Women with a known allergy to proflavine or acriflavine
+Patients with allergy to regadenoson
+Known allergy to iodine or intravenous contrast agent.
+Known allergy or anaphylactic reaction to indocyanine green (ICG).
+Previous intravenous (IV) contrast allergy
+Severe food or medication allergy
+Allergy to gadolinium or other severe drug allergies
+Known allergy to proflavine or acriflavine
+Patient with allergy to contrast agent
+History of allergy to iodine
+History of multiple food and/or drug allergy
+Has a known allergy to dextran or VBD (if intended to be used)
+Known allergy to gadolinium.
+Patients with known hypersensitivity or allergy to any component of Sonazoid.
+No allergy to gadolinium
+Patients with known hypersensitivity or allergy to any component of Definity
+Any known allergy or prior reaction to fluorescein; also, a positive skin prick test to fluorescein is considered an exclusion criteria and the patient would not be eligible for entry into this study
+History of any anaphylactic reaction, any severe allergy, or any allergy to folate
+Patients with allergy to iodinated contrast
+Subjects who have a known allergy to iron
+History of clinically significant sensitivity or allergy to monoclonal antibodies, their excipients, or intravenous gamma globulin
+Allergy to fluorescein
+Allergy to CT contrast media requiring the administration of steroid prophylaxis
+Allergy to intravenous CT contrast media
+Has a known allergy to dextran
+Known allergy to gadolinium containing contrast agents
+Known allergy to FdCyd
+Subjects with known hypersensitivity and allergy to gadolinium contrast agents
+Documented or reported contrast allergy
+Have a known allergy to iodinated contrast agent
+NORMAL VOLUNTEERS: Have a known allergy to iodinated contrast agent
+Iodine allergy, hyperthyroidism, or Grave’s disease
+The patient has a documented intravenous contrast allergy or iodine allergy
+Patient must not have a history of allergy or bronchial asthma
+Allergy to fluoroquinolones
+Allergy to any component of sipuleucel-T
+Allergy to Brussels sprouts
+Participants with a known or suspected allergy to iodine
+Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
+Known allergy or hypersensitivity to monoclonal antibodies
+Participants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction, sulfonamide allergy
+No known sensitivity or allergy to nonsteroidal anti-inflammatory drugs (NSAIDs)
+Nut or seed allergy
+No known allergy to tree nuts
+History of allergy to any of the components of OTL38, including folic acid
+Allergy or hypersensitivity to components of the GDC-0994 formulation
+Has a known history of hypersensitivity or allergy to pembrolizumab and any of its components and/or to any of the study chemotherapies (e.g., nab-paclitaxel, paclitaxel, gemcitabine, or carboplatin) and any of their components.
+Participant must not have a history of allergy to erlotinib